Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within the tumor, leading to the evolution of multiple resistance mechanisms.
The research team, led by Lauren Averett...
The University of Texas MD Anderson Cancer Center supports the United States Surgeon General’s actions to inform youth, parents, teachers...
Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and...
In his first interview since leaving public office in March, former U.S. Secretary of State Rex Tillerson spoke to CBS News' Bob Schieffer about the state of domestic and world affairs at a dinner Dec. 6 benefiting The University of Texas MD Anderson Cancer Center. More than 850 MD Anderson supporters attended the 10th annual A Conversation With a Living Legend® in Houston, which raised more than $1.78 million for cancer research...
A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent...
MD Anderson extends deepest sympathy to the family of former President George H.W. Bush. The institution mourns the loss of an extraordinary...
The University of Texas MD Anderson Cancer Center and the Houston Dynamo today announced plans to work together toward one goal: end cancer...
Two leaders in the field of melanoma treatment – a surgeon and an oncologist – from The University of Texas MD Anderson Cancer Center have...
Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new...
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit...
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp...
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called...
The University of Texas MD Anderson Cancer Center today formally opened a four-story facility in League City that houses new and expanded...
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused...
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated...
When comparing standard-of-care surgical options for women with early-stage cervical cancer, two studies led by researchers at The University...
Thanks to a grassroots campaign at Houston-area Walmart stores and generous support from individuals, teams and other corporate sponsors,...
Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy....
Frances MacDonald, a clinical nurse in the GI-Colorectal Center at The University of Texas MD Anderson Cancer Center, is the recipient of...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma...
Radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage 4 disease...
A Conversation With a Living Legend®, an annual luncheon benefiting The University of Texas MD Anderson Cancer Center, will pay tribute to...
An emerging treatment known as adoptive T-cell therapy has proven effective in a Phase II clinical trial for treating progressive multifocal...
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma...
The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement...
Cattlemen for Cancer Research (CCR) will hold its 20th annual auction in Bastrop, Texas, Saturday, Oct. 20, at the Hills Prairie Livestock...
Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform at The University of Texas...
Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform at The University of Texas MD Anderson Cancer...
A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related...
A Conversation With a Living Legend® in Dallas will honor PGA TOUR professional Jordan Spieth, Nov. 5 at the Hilton Anatole. CBS Sports'...
A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide unprecedented response rates among...
The University of Texas MD Anderson Cancer Center today joined with more than 450 communities and institutions across the country in hosting...
In the largest study of long-term safety outcomes for patients with breast implants, researchers at The University of Texas MD Anderson Cancer...
Padmanee Sharma, M.D., Ph.D., is the 2018 recipient of the Julie and Ben Rogers Award for Excellence in Research at The University of Texas...
Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD Anderson...
Researchers at The University of Texas MD Anderson Cancer Center have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor...
New research in women with HER2+ breast cancer found no difference in disease-free survival (DFS) and overall survival (OS) when receiving...
A drug revived by researchers at The University of Texas MD Anderson Cancer Center continues to provide high response rates among stage 4...
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed advisory board of volunteers who advance...
The University of Texas MD Anderson Cancer Center today was awarded $30 million to support research, core facilities, recruitment and prevention...
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the...
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended...
The University of Texas MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best...
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a...
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children...
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer...
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing...
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center...
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival...
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors...
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug,...
The University of Texas MD Anderson Cancer Center will host its 20th annual Making Cancer History® seminar in Aspen, 10 a.m.-12 p.m. Monday...
In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center adding the PARP inhibitor veliparib...
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and TRACTION...
Recognizing that vaccination rates for the human papillomavirus (HPV) remain low across the U.S., particularly in Texas, The University of...
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family Fellows. As...
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of...
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson...
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR...
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable...
Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival...
The University of Texas MD Anderson Cancer Center today sent letters to individuals whose email addresses were accidentally exposed in a communication...
The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating...
The American Society of Clinical Oncology (ASCO) will present awards to leaders of cancer care during its annual meeting June 1-5 in Chicago...
The University of Texas MD Anderson and Ipsen, a global biopharmaceutical group, today announced a global licensing and joint development...
While some regions of the nation will experience greater nursing shortages than others in the coming years, hospitals and healthcare systems...
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity...
Abstract: 6063
A study led by researchers at The University of Texas MD Anderson Cancer Center found that the use of at-home sensor...
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical...
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to...
The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by...
If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD...
Founding TMC3 institutions – Texas Medical Center (TMC), Baylor College of Medicine, Texas A&M University Health Science Center, The University...
A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable...
Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary...
The University of Texas MD Anderson Cancer Center will host free skin cancer screenings from 10 a.m. – 1 p.m. on Saturday, May 5 at two of...
Richard D. Wood, Ph.D., professor at The University of Texas MD Anderson Cancer Center, has been elected as a member of the American Academy...
A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the...
Just like people, some T cells have excellent memories. These subtypes known as memory T cells may explain why some immunotherapies are more...
Special Note: All prom events are open to media, including the dress and tux selection, and hair and makeup appointments.
The...
Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation...
A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug...
Country music fans and polo enthusiasts alike are expected at the 32nd annual Polo on the Prairie, an annual polo match and fundraising event...
Researchers from The University of Texas MD Anderson Cancer Center have found a startling amount of new information about molecular features...
At the heart of any cancer diagnosis or treatment are cells. If one thinks of the cell components controlling gene activation as a Russian...
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Midland, 11:30 a.m. to 1:30 p.m.,...
The University of Texas MD Anderson Cancer Center and Berkeley Lights, Inc. today announced the launch of Optera Therapeutics Corp, a biopharmaceutical...
A powerful resistance mutation that appeared to emerge in melanoma after a patient received a targeted therapy combination, instead was lurking...
The University of Texas MD Anderson Cancer Center today celebrated a milestone in the construction of its three-story clinic in The Woodlands...
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing...
The University of Texas MD Anderson Cancer Center was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas...
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages...
Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal...
A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma...
Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone cancer that accounts for one-fourth of all breast cancers, could...
The University of Texas MD Anderson Cancer Center and its 20,000 faculty and staff devoted exclusively to patient care, research, education...
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas...
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared...
Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive...
The University of Texas MD Anderson Cancer Center and UT Health San Antonio applaud the actions of the San Antonio City Council today in voting...
Leaders of The University of Texas MD Anderson Cancer Center will head to Palm Beach Jan. 22 to present innovations in cancer research, treatment...
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to...
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management...